Sugi Predict

Sugi Predict / Compounds / SCHEMBL3244153

SCHEMBL3244153

SCHEMBL3244153

O=C(O)c1ccc2cc3n(c2c1)C=CCc1ccccc1-3

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 2/20 0.43
▸ SRD5A1 P18405 1/20 0.43
▸ POLB P06746 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TTR P02766 1/20 0.37
▸ ACLY P53396 2/20 0.36
▸ PTPRC P08575 2/20 0.36
▸ FGFR1 P11362 1/20 0.34
▸ KDM4A O75164 1/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.34
▸ KDM5B Q9UGL1 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MITF O75030 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ AKR1C3 P42330 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL841837 0.89 RPS6KA3 (0.41) KMT2AALDH1A1RAB9AKDM4EMEN1
SCHEMBL4830030 0.83 SLC22A12 (0.35) —
SCHEMBL4831483 0.81 SMN1; SMN2 (0.36) SRD5A2SRD5A1POLBKMT2AACLY
SCHEMBL732858 0.81 KMT2A (0.37) KMT2AALDH1A1RAB9AKDM4EHPGD
SCHEMBL3943354 0.80 SRD5A2 (0.48) SRD5A2SRD5A1POLBKMT2ATTR
SCHEMBL3075059 0.79 TBXA2R (0.36) SRD5A2SRD5A1POLBKMT2ATTR
SCHEMBL4139797 0.76 KMT2A (0.37) SRD5A2SRD5A1POLBKMT2ATTR
SCHEMBL4825624 0.75 CA12 (0.35) POLBKMT2AACLYFGFR1KDM4A
SCHEMBL2156291 0.75 NOTUM (0.42) SRD5A2SRD5A1ALDH1A1KDM4EHPGD
SCHEMBL3574670 0.74 SRD5A2 (0.50) SRD5A2SRD5A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118110-B1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-07-25 — — EP disclosed
EP-2396329-A1 Compounds for the treatment of hepatitis c Bristol-Myers Squibb Company (US) 2011-12-21 — — EP disclosed
EP-1987038-B1 HCV NS5B INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2010-10-06 — — EP disclosed
WO-2010093359-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-19 — — WO disclosed
EP-2029606-B1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2010-05-26 — — EP disclosed
EP-2183252-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2010-05-12 — — EP disclosed
EP-2121694-A1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS Bristol-Myers Squibb Company (US) 2009-11-25 — — EP disclosed
EP-2118110-A1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS Bristol-Myers Squibb Company (US) 2009-11-18 — — EP disclosed
WO-2009029384-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-05 — — WO disclosed
EP-2029606-A2 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS Brystol-Myers Squibb Company (US) 2009-03-04 — — EP disclosed
WO-2007092000-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2007-08-16 — — WO disclosed
US-20070185083-A1 HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-08-09 — — US disclosed
US-20070184024-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-08-09 — — US disclosed
EP-1776368-A1 INHIBITORS OF HCV REPLICATION Bristol-Myers Squibb Company (US) 2007-04-25 — — EP disclosed
US-20070078122-A1 Indolobenzazepine HCV NS5B inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 — — US disclosed
WO-2007033175-A1 INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-22 — — WO disclosed
WO-2007033032-A1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-22 — — WO disclosed
US-20070060565-A1 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-03-15 — — US disclosed
US-20060166964-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-07-27 — — US disclosed
WO-2006020082-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070184024-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors ZC3HAV1, CYP3A5, SLC10A1 SRD5A2 862/4885SRD5A1 520/4885POLB 2034/4885
US-20070078122-A1 Indolobenzazepine HCV NS5B inhibitors HTR3C, IDO1, HTR3B SRD5A2 1318/4885SRD5A1 1306/4885POLB 811/4885
US-20070060565-A1 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors ZC3HAV1, CYP3A5, SLC10A1 SRD5A2 862/4885SRD5A1 520/4885POLB 2034/4885
US-20060166964-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 SRD5A2 1662/4885SRD5A1 990/4885POLB 89/4885
US-20070185083-A1 HCV NS5B Inhibitors EIF2AK2, HAVCR2, EIF5B SRD5A2 1410/4885SRD5A1 951/4885POLB 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.